drugset / Trial / NCT04544826
A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses
RandomizedSequentialDouble-blindOther
Summary
The purpose of the study is to assess the safety and tolerability of JNJ-77474462 following single subcutaneous (SC) administration to healthy participants of Japanese descent.
Timeline
- Start
- 2020-10-16
- Primary completion
- 2021-08-05
- Completion
- 2021-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bermekimab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.